The correlation between decreased FBXO9 expression and unfavorable survival outcomes further emphasized the clinical importance of our findings, thus highlighting FBXO9 as a promising prognostic marker and a potential therapeutic target for lung cancer. This evidence concerns the gene FBXO9 and lung carcinoma.